Transfection

Cytiva strengthens cell line development with CEVEC acquisition

Retrieved on: 
Thursday, October 6, 2022
Therapy, RNA transfection, Technology, Efficiency, PCL, Patient, Research, Twitter, Tissue, Cell, Drug discovery, AAV, Industry, Genome, Solution, Transfection, Vaccine, Adenoviridae

46 scientific experts based in Cologne, Germany, join the Cytiva teaminthegenomic medicine space

Key Points: 
  • 46 scientific experts based in Cologne, Germany, join the Cytiva teaminthegenomic medicine space
    AMERSHAM, England, Oct. 6, 2022 /PRNewswire/ -- Global life sciences leader Cytiva has acquired CEVEC Pharmaceuticals, a leading German provider of high-performance cell line development and viral vector manufacturing technologies.
  • Emmanuel Abate, President, Genomic Medicine at Cytiva, says: "Cevec's innovative technology complements Cytiva's offering and brings the promise of improved viral vector manufacturing.
  • Producer Cell Lines (PCLs) as enabled by CEVEC's ELEVECTA Technology enable yield, scalability, and robustness in the manufacturing process.
  • CEVEC and its 46 scientific experts will become part of Cytiva with immediate effect.

Oxford Biomedica Solutions to Present Company Capabilities & Its Platform at Cell & Gene Meeting on the Mesa and European Society of Gene & Cell Therapy

Retrieved on: 
Wednesday, October 5, 2022
Poster, ESGCT, AAV, Oxford BioMedica, Transfection, Paint

Virtual attendance is available which includes a livestream of Oxford Biomedica Solutions presentation and the ability to view all conference sessions on-demand.

Key Points: 
  • Virtual attendance is available which includes a livestream of Oxford Biomedica Solutions presentation and the ability to view all conference sessions on-demand.
  • The Oxford Biomedica Solutions platform has now demonstrated performance of 1E15 vg/L titer, greater than 90% fully intact vector, formulation stability at 2-8C, and consistency across hundreds of constructs and all serotypes tested.
  • A sampling of the technical breadth and capability will be shared at the upcoming ESGCT conference.
  • Achieving AAV vector productivity >1E15 vg/L and scaling suspension transfection to 2,000L through upstream process optimization.

Global Transfection Technologies Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022
Science, Other Science, Biotechnology, Oncology, Health, Infectious Diseases, Genetics, Clinical Trials, Adoption, Transfection, COVID-19, Prevalence, Virus, Oligonucleotide, Electroporation, RNA interference, Growth, Industry, Government, Investment, Cancer, Technology, Protein, Cell, Method, Vivo, RNA, Research, DNA, Reporter gene, R, Gene expression, Pharmaceutical industry, Vaccine, Potash

It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection.

Key Points: 
  • It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection.
  • Key Questions Answered in This Report:
    How has the global transfection technologies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global transfection technologies market?
  • What is the structure of the global transfection technologies market and who are the key players?

Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers

Retrieved on: 
Tuesday, September 27, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Adult, Health, Particle-size distribution, Fisher Scientific, Laboratory, Cdx, FDA, Food, NSCLC, Thermo Fisher Scientific, Mindful Scientific Inc., Pharmaceutical Services Negotiating Committee, Invitrogen, Applied Biosystems, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transfection, MTC, PPD, Patheon, Science, RET, NGS, Research, Pharmaceutical industry

This marks the Oncomine Dx Target Tests first approval as a CDx for a therapy targeting RET-positive thyroid cancer and second approval associated with RET-positive NSCLC.

Key Points: 
  • This marks the Oncomine Dx Target Tests first approval as a CDx for a therapy targeting RET-positive thyroid cancer and second approval associated with RET-positive NSCLC.
  • Initially approved in 2020, Retevmo is a selective RET kinase inhibitor and was the first therapy approved for patients with advanced RET-driven lung and thyroid cancers.
  • It is also approved in Japan as a companion diagnostic for Retevmo in the same indications.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

Global Viral Vector & Plasmid DNA Manufacturing Market Report 2022: Facility Expansion for Cell and Gene Therapies Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022
Genetics, Health Technology, Health, Observation, Porter's five forces analysis, Immortalised cell line, COVID-19, RNA interference, Downstream processing, Risk, Global Viral, Adeno-associated virus, Geography, Adenoviridae, Growth, Ansoff Matrix, Industry, Market development, Sense (molecular biology), Bioprocess, USD, Workflow, Infection, Cell therapy, SWOT, Genetic disorder, CAGR, Vaccine, Transfection, Lentivirus, Application, Purification, Vaccine, Cancer

The Global Viral Vector & Plasmid DNA Manufacturing Market is segmented based on Cell Line, Type, Transfection, Indication, Workflow, Application, and Geography.

Key Points: 
  • The Global Viral Vector & Plasmid DNA Manufacturing Market is segmented based on Cell Line, Type, Transfection, Indication, Workflow, Application, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Viral Vector & Plasmid DNA Manufacturing Market.
  • The Global Viral Vector & Plasmid DNA Manufacturing Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Viral Vector & Plasmid DNA Manufacturing Market.

EQS-News: CEVEC Pharmaceuticals GmbH: ROKOTE Laboratories licenses CEVEC’s CAP® Ad Technology for vaccine manufacturing

Retrieved on: 
Tuesday, September 20, 2022
Safety, Infection, Immunodeficiency, Development, Human, COVID-19, Risk, AAV, Disease, FDA, Research, Bioreactor, Severe acute respiratory syndrome coronavirus 2, Company, Business Finland, Patient, RSV, Laboratory, Transfection, Technology, Vaccine, RCA, EUR, University, GMP, Pharmaceutical industry

Under the agreement, CEVEC has granted ROKOTE Laboratories Finland Ltd non-exclusive rights to use the CAP Ad platform for the manufacturing of adeno-based vaccines for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV infections.

Key Points: 
  • Under the agreement, CEVEC has granted ROKOTE Laboratories Finland Ltd non-exclusive rights to use the CAP Ad platform for the manufacturing of adeno-based vaccines for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV infections.
  • We are very pleased that ROKOTE Laboratories Finland Ltd will build on the CAP Ad Technology and we are proud that we can contribute to combating the ongoing COVID-19 pandemic with a technology that makes a real difference in vaccine safety, said Dr. Nicole Faust, Chief Executive Officer of CEVEC.
  • Our CAP Ad Technology ensures that the risk of potential adverse effects due to contaminating replication-competent adenovirus is as low as possible.
  • The CAP Ad Technology is an innovative technology platform developed by CEVEC for the scalable production of RCA-free adenoviral vectors for gene therapy applications and vaccines.

Tyra Biosciences to Participate at September 2022 Investor Conferences

Retrieved on: 
Thursday, September 8, 2022
CA, Achondroplasia, Cancer, Fibroblast growth factor receptor 1, SNP, FGFR, Fibroblast growth factor receptor, RET, LinkedIn, Science, FGFR4, Chromosomal rearrangement, Nasdaq, Transfection, FGFR2, FGFR3, Patient, Medical imaging, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:

Key Points: 
  • CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:
    Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • Leveraging SNP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers.
  • TYRA-200 is an FGFR2 inhibitor that TYRA is developing initially in intrahepatic cholangiocarcinoma.
  • TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and REarranged during Transfection kinase (RET) related cancers.

Lilly Announces Details of Presentations at ESMO Congress 2022

Retrieved on: 
Wednesday, September 7, 2022
Patient, Breast cancer, Cyclin D1, Cell cycle, Technology, Food and Drug Administration, Preclinical development, S phase, Man, Recurrence, RET, Rb, EBC, Food, Transfection, CDK, Traffic barrier, Lilly, Tamoxifen, Plasma, FDA, Phosphorylation, Breast cancer classification, Adult, ET, Cell death, Cell proliferation, Cerebrospinal fluid, Woman, Growth, Apoptosis, Cyclin-dependent kinase, Retinoblastoma protein, Pharmaceutical industry, Medical imaging, Abemaciclib, G1

A Grade 3 decrease in neutrophil count (based on laboratory findings) occurred in 19 to 32% of patients receiving Verzenio.

Key Points: 
  • A Grade 3 decrease in neutrophil count (based on laboratory findings) occurred in 19 to 32% of patients receiving Verzenio.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.
  • P-LLY
    Verzenio and Retevmo are trademarks owned by or licensed toEli Lilly and Company, its subsidiaries, or affiliates.
  • Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Cell Counting Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Other Science, Science, Danaher Corporation, Conditional sentence, Technology, Cancer, Cell, Obesity, Spectrophotometry, Research, Smoking, Exercise, Regenerative medicine, Hematology, Virus, Solution, Risk, Asia-Pacific, Infection, Radiation, Inflammation, Transfection, Diagnosis, Hormone, Quality of life, American Cancer Society, Organization, Hospital, Data visualization, List of life sciences, Health, GE, Carcinogen, Prevalence, Hemocytometer, Biotechnology, Population, Efficiency, General Electric Company, Sutro Biopharma, Acquisition, Growth, Danaher, Fine chemical, Vaccine, Dietary supplement

The "Cell Counting Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Counting Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The cell counting market consists of sales of cell counting by entities (organizations, sole traders, partnerships) that refer to any of techniques used for counting cells or quantification of cells in the life sciences for diagnosis and treatment.
  • The growing prevalence of cancer amongst the global population is the major factor expected to drive the growth of the cell counting market.
  • Therefore, the growing prevalence of cancer amongst the global population drives the growth of the cell counting market.

Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress

Retrieved on: 
Monday, September 5, 2022
European Society for Medical Oncology, Investigational New Drug, COVID-19, CA, Security (finance), CEO, Achondroplasia, Cancer, MTD, Research, Form 10-K, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fibroblast growth factor receptor 2, SNP, FGFR, Fibroblast growth factor receptor, Risk, FGFR3, RET, Hyperphosphatemia, FGFR1, Food, ESMO, LinkedIn, Science, SEC, Time-invariant system, Vinylcyclopropane rearrangement, U.S. Securities and Exchange Commission, Nasdaq, Company, FDA, Oncology, Transfection, FGFR2, Congress, Annual report, Private Securities Litigation Reform Act, Trial of the century, Patient, Pharmaceutical industry, Cholangiocarcinoma

"We believe the preclinical results being presented at the ESMO Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class," said Todd Harris, CEO of TYRA.

Key Points: 
  • "We believe the preclinical results being presented at the ESMO Congress showcase the enhanced anti-tumor activity and selectivity of TYRA-300 as compared to other agents in the class," said Todd Harris, CEO of TYRA.
  • Details of the poster presentation are as follows:
    Regular abstracts will be published on the ESMO website on September 5, 2022.
  • The poster presentation on TYRA-300 will be made available on the TYRA website under the "For Investors" section on September 12, 2022.
  • TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.